RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Integrating network pharmacology and transcriptomics to identify solasonine's anti-osteosarcoma targets and experimental validation.
Integrating network pharmacology and transcriptomics to identify solasonine's anti-osteosarcoma targets and experimental validation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在本研究中,ATP1A1、CLK1、SIGMAR1、PYGM 和 HSP90B1 被确定为 solasonine 治疗 OS 的关键靶点,并发现它们对 OS 的治疗具有参考意义。SS 可能成为治疗骨肉瘤的潜在药物。
骨肉瘤(OS)患者面临有效治疗药物较少的挑战。澳洲茄碱(SS)是中药中抗OS细胞的活性成分。本研究旨在确定澳洲茄碱治疗OS的关键靶点。
本研究首先从公共数据库下载转录组数据及相关基因集。随后,将差异表达基因(DEGs)与solasonine及OS疾病靶点取交集,获得候选靶点。接着通过回归分析鉴定关键靶点,并构建预后模型。随后利用关键靶点构建列线图。之后分析这些关键靶点的功能与免疫微环境,以及其结构、调控网络和分子对接。在RT-qPCR实验中验证候选靶点在骨肉瘤细胞中的表达水平,并验证solasonine对骨肉瘤细胞恶性生物学行为的影响。
DEGs、与solasonine对应的靶点以及OS相关疾病靶点取交集,获得37个候选靶点。随后的回归分析确定了5个关键靶点(ATP1A1、CLK1、SIGMAR1、PYGM、HSP90B1)。进一步证明,使用这些关键靶点构建的OS预后模型是稳健的。构建的列线图提供了极好的预测模型。此外,一些通路,如细胞因子-细胞因子受体相互作用,显著富集,并且有4种显著不同的免疫细胞和3个显著不同的免疫检查点(P<0.05)。另外,NK 细胞和活化B细胞显著正相关(cor = 0.68,P < 0.001)。随后的调控网络包括调控这5个靶点的转录因子。所有关键靶点均显示出与SS良好的分子对接效果。这些靶基因在骨肉瘤细胞系中均表现出更高的表达(P<0.05)。Solasonine可抑制细胞增殖、迁移和侵袭的恶性生物学行为。
Osteosarcoma (OS) patients face the challenge of having few effective therapeutic drugs. Solasonine(SS)is an active component of TCM against OS cells. This study aims to identify the key targets of solasonine in treating OS.
In this study, the transcriptome data and related gene sets were first downloaded from public databases. Subsequently, candidate targets were obtained by intersecting differentially expressed genes (DEGs) with solasonine and OS disease targets. Key targets were then identified through regression analyses, and a prognostic model was constructed. A nomogram was subsequently constructed using the key targets. The functions and immune microenvironment, as well as the structure, regulatory network, and molecular docking of these key targets, were then analyzed. The expression level of the candidate targets in osteosarcoma cells was verified in RT-qPCR experiments, and the effect of solasonine on the malignant biological behavior of osteosarcoma cells was verified.
DEGs, targets corresponding to solasonine, and OS-related disease targets were intersected to obtain 37 candidate targets. Subsequent regression analyses identified 5 key targets (ATP1A1, CLK1, SIGMAR1, PYGM, HSP90B1). It was further demonstrated that the OS prognostic model constructed using these key targets was robust. The constructed nomogram provided an excellent predictive model. Moreover, some pathways, such as cytokine-cytokine receptor interaction, were significantly enriched, and there were 4 significantly different immune cells and 3 significantly different immune checkpoints ( P<0.05 ). Additionally, natural killer cells and activated B cells were significantly positively correlated (cor = 0.68, P < 0.001 ). The subsequent regulatory network included transcription factors regulating the 5 targets. All key targets showed favorable molecular docking effects with SS. The target genes all exhibited higher expression in osteosarcoma cell lines( P<0.05 ). Solasonine can inhibit the malignant biological behavior of cell proliferation, migration and invasion.
In this study, ATP1A1, CLK1, SIGMAR1, PYGM, and HSP90B1 were identified as key targets of solasonine in the treatment of OS, and they were found to have reference significance for the treatment of OS. SS can be a potential drug for the treatment of osteosarcoma.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。